HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

Hinge Health 64.6% three-month rally is backed by surging revenues, wider margins and a raised 2026 outlook, but execution expectations are rising.

Whether it be online shopping or social media, secular forces are propelling consumer internet businesses forward. But it’s not all sunshine and rainbows as consumer purchasing power can make or break demand. This unpredictability is weighing on the industry as its 7.6% return over the past six months has fallen short of the S&P 500’s 11.7% gain.

Insurance demand accelerates faster than expected, straining provider capacity.

BetterHelp remains Teladoc’s biggest headache as customers shift toward insurance-covered therapy and provider capacity struggles to keep up.

Digital medical services platform Teladoc Health (NYSE:TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 15.5% above analysts’ consensus estimates.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Teladoc Health (TDOC) shares came under focus after the company reported second quarter 2026 results, which showed lower sales and a wider net loss, alongside fresh revenue and earnings guidance for the rest of the year. See our latest analysis for Teladoc Health. The earnings release and updated guidance appear to be weighing heavily on sentiment. Teladoc Health's share price return is down 28.32% over the past day and 24.02% over the past week, while the 1-year total shareholder return has...

Teladoc stock sinks on disappointing Q2 revenue and future guidance. Here’s why caution is warranted in buying the dip in TDOC shares today.

Today, July 30, 2026, investors are pivoting back into technology despite GDP slowdown, with the Nasdaq climbing on broad semiconductor strength.

Shares of Teladoc Health fell more than 25% Thursday after the telehealth company missed second-quarter revenue expectations and cut its full-year sales forecast. The pain is concentrated in BetterHelp, Teladoc's therapy and psychiatry platform, where revenue fell 12% to $212.6 million. Teladoc has pushed BetterHelp users toward insurance-covered therapy instead of cash-pay sessions.

TDOC tops adjusted earnings estimates despite a revenue miss, as Integrated Care and international growth help cushion BetterHelp weakness and a lower 2026 outlook.

Moby summary of Teladoc Health, Inc.'s Q2 2026 earnings call

Teladoc Health (NYSE:TDOC) reported second-quarter results within its consolidated guidance range, supported by stronger-than-expected profitability in its Integrated Care segment, while lower cash-pay revenue at BetterHelp prompted the company to reduce its full-year revenue outlook. Consolidated

Demand for the mental health unit’s insurance offering accelerated faster than expected, eating into its cash pay business. The quarter marked an “unfortunate setback” for BetterHelp, one analyst said.

Teladoc Health (TDOC) reported a Q2 loss late Wednesday of $0.21 per diluted share, wider than a los

In late July 2026, Teladoc Health, Inc. reported second-quarter 2026 results showing sales of US$606.93 million and a net loss of US$38.91 million, with both revenue and per-share loss slightly weaker than the same period a year earlier. Over the first half of 2026, Teladoc’s sales declined to US$1.22 billion while its net loss narrowed to US$102.75 million, indicating that cost controls and efficiency measures may be helping even as top-line growth remains under pressure. We will now...

The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Teladoc (TDOC) delivered earnings and revenue surprises of +12.50% and -1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Digital medical services platform Teladoc Health (NYSE:TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 17.4% above analysts’ consensus estimates.

Teladoc Health stock is coming off a very steep 5 year decline. Current checks suggest the shares may now be trading below a reasonable estimate of intrinsic value, with both the Discounted Cash Flow (DCF) work and market based multiples pointing to upside at the recent US$9.36 close. Teladoc Health shareholders have seen the stock fall 93.8% over the past 5 years, which means any current valuation gap matters a lot for investors who are reassessing the long term case. The planned Teladoc...

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Digital medical services platform Teladoc Health (NYSE:TDOC) will be announcing earnings results this Wednesday after the bell. Here’s what investors should know.

HCA (HCA) delivered earnings and revenue surprises of +0.26% and 0.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A new ChatGPT feature allows users to securely connect personal health data, enabling more personalized, context-aware responses to everyday health questions.

The latest trading day saw Teladoc (TDOC) settling at $9.65, representing a +2.33% change from its previous close.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.